MiR-146a encapsulated liposomes reduce vascular inflammatory responses through decrease of ICAM-1 expression, macrophage activation, and foam cell formation

Ho, Donald Ming‐Tak; Lynd, Tyler; Jun, Claire; Shin, Juhee; Millican, R. Carl; Estep, Benjamin K.; Zhang, Xixi; Brott, Brigitta C.; Kim, Dong Ho; Sherwood, Jennifer; Hwang, Patrick T.J.

doi:10.1039/d2nr03280e

Cited by 10 publications

(4 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to studies, a 4-10% PEG growth on the liposome surface lengthens its in vivo circulation time from 200 to 1000 min. Proteins, peptides, and other molecules can be chemically conjugated to the liposomes' outer surface to create modified liposomes with the required controlled properties [70]. Liposomes can also be made to be pH-sensitive by utilizing pH-sensitive components, allowing for a pH-dependent release of drugs from the vesicles.…”

Section: Liposomes-drug/gene Delivery Systemsmentioning

confidence: 99%

Organic Nanoparticles in Progressing Cardiovascular Disease Treatment and Diagnosis

Udriște,

Burdușel,

Niculescu

et al. 2024

Polymers

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs), the world’s most prominent cause of mortality, continue to be challenging conditions for patients, physicians, and researchers alike. CVDs comprise a wide range of illnesses affecting the heart, blood vessels, and the blood that flows through and between them. Advances in nanomedicine, a discipline focused on improving patient outcomes through revolutionary treatments, imaging agents, and ex vivo diagnostics, have created enthusiasm for overcoming limitations in CVDs’ therapeutic and diagnostic landscapes. Nanomedicine can be involved in clinical purposes for CVD through the augmentation of cardiac or heart-related biomaterials, which can be functionally, mechanically, immunologically, and electrically improved by incorporating nanomaterials; vasculature applications, which involve systemically injected nanotherapeutics and imaging nanodiagnostics, nano-enabled biomaterials, or tissue-nanoengineered solutions; and enhancement of sensitivity and/or specificity of ex vivo diagnostic devices for patient samples. Therefore, this review discusses the latest studies based on applying organic nanoparticles in cardiovascular illness, including drug-conjugated polymers, lipid nanoparticles, and micelles. Following the revised information, it can be concluded that organic nanoparticles may be the most appropriate type of treatment for cardiovascular diseases due to their biocompatibility and capacity to integrate various drugs.

show abstract

Section: Liposomes-drug/gene Delivery Systemsmentioning

confidence: 99%

Organic Nanoparticles in Progressing Cardiovascular Disease Treatment and Diagnosis

Udriște,

Burdușel,

Niculescu

et al. 2024

Polymers

View full text Add to dashboard Cite

show abstract

“…[ 205 ] In addition, liposomes have also been utilized for targeted delivery of gene regulators such as NLRP3 siRNA which inhibits the formation of inflammasomes and miRNA‐146a which restricts NF‐κB inflammation pathway activation. [ 206 ] Interestingly, Wu et al. designed an apoptotic body biomimetic nanoliposome (AP‐Lipo) to deliver drug to the atherosclerotic macrophages with maximum efficiency to reduce plaque burden.…”

Section: Therapymentioning

confidence: 99%

Nanomedicine for Diagnosis and Treatment of Atherosclerosis

Cheng,

Huang,

Chen

et al. 2023

Advanced Science

View full text Add to dashboard Cite

With the changing disease spectrum, atherosclerosis has become increasingly prevalent worldwide and the associated diseases have emerged as the leading cause of death. Due to their fascinating physical, chemical, and biological characteristics, nanomaterials are regarded as a promising tool to tackle enormous challenges in medicine. The emerging discipline of nanomedicine has filled a huge application gap in the atherosclerotic field, ushering a new generation of diagnosis and treatment strategies. Herein, based on the essential pathogenic contributors of atherogenesis, as well as the distinct composition/structural characteristics, synthesis strategies, and surface design of nanoplatforms, the three major application branches (nanodiagnosis, nanotherapy, and nanotheranostic) of nanomedicine in atherosclerosis are elaborated. Then, state‐of‐art studies containing a sequence of representative and significant achievements are summarized in detail with an emphasis on the intrinsic interaction/relationship between nanomedicines and atherosclerosis. Particularly, attention is paid to the biosafety of nanomedicines, which aims to pave the way for future clinical translation of this burgeoning field. Finally, this comprehensive review is concluded by proposing unresolved key scientific issues and sharing the vision and expectation for the future, fully elucidating the closed loop from atherogenesis to the application paradigm of nanomedicines for advancing the early achievement of clinical applications.

show abstract

“…[ 49 ] Furthermore, ICAM‐1 linkage to monocytes has been shown to trigger trans‐endothelial migrations of monocytes under conditions that mimic inflammation. [ 50 ] Thus, the upregulation of ICAM‐1 serves as a pivotal factor in driving the inflammatory response.…”

Section: Targeting Molecules In Monocyte Recruitmentmentioning

confidence: 99%

Advances in the treatment of atherosclerosis with ligand‐modified nanocarriers

Deng,

Wang,

et al. 2023

Exploration

View full text Add to dashboard Cite

Atherosclerosis, a chronic disease associated with metabolism, poses a significant risk to human well‐being. Currently, existing treatments for atherosclerosis lack sufficient efficiency, while the utilization of surface‐modified nanoparticles holds the potential to deliver highly effective therapeutic outcomes. These nanoparticles can target and bind to specific receptors that are abnormally over‐expressed in atherosclerotic conditions. This paper reviews recent research (2018–present) advances in various ligand‐modified nanoparticle systems targeting atherosclerosis by specifically targeting signature molecules in the hope of precise treatment at the molecular level and concludes with a discussion of the challenges and prospects in this field. The intention of this review is to inspire novel concepts for the design and advancement of targeted nanomedicines tailored specifically for the treatment of atherosclerosis.

show abstract

MiR-146a encapsulated liposomes reduce vascular inflammatory responses through decrease of ICAM-1 expression, macrophage activation, and foam cell formation

Abstract: Vascular insults can create an inflammatory cascade involving endothelial cell, smooth muscle cell, and macrophage activation which can eventually lead to vascular disease such as atherosclerosis. Several studies have identified...

Cited by 10 publications

References 56 publications

Organic Nanoparticles in Progressing Cardiovascular Disease Treatment and Diagnosis

Organic Nanoparticles in Progressing Cardiovascular Disease Treatment and Diagnosis

Nanomedicine for Diagnosis and Treatment of Atherosclerosis

Advances in the treatment of atherosclerosis with ligand‐modified nanocarriers

Contact Info

Product

Resources

About